GLP-2 analogue 10   Click here for help

GtoPdb Ligand ID: 9896

Immunopharmacology Ligand
Comment: This GLP-2 analogue (peptide 10 in [3]) was designed to increase the peptide's metabolic stability (and in vivo pharmacokinetic profile) beyond that of the clinically approved DPP4 resistant GLP-2 analogue teduglutide, with the aim of providing sustained therapeutic effects. GLP-2 analogue 10 achieves increased half-life by the incorporation of a covalent Cys-mediated side-chain cross-link (or staple) that stabilises the α-helical conformation of the peptide. The terminal PSSGAPPPS sequence of 10 is the C-terminal extension of exendin-4 which improves the peptide's solubility.
The intestinotrophic effects of GLP-2 (e.g. promotion of intestinal growth, reduced epithelial cell apoptosis and inflammation) has led to the development of GLP-2 analogues for the treatment of GI disorders such as short bowel syndrome, inflammatory bowel diseases and potentially other intestinal insufficiency diseases.
Click here for help
Bioactivity Comments
GLP-2 analogue 10 exhibits more effective anti-inflammatory effects in mouse models of DSS-induced colitis than teduglutide [3]. The half-life of GLP-2 analogue 10 is 4.7 hours after i.v. administration, in contrast to teduglutide's half-life of 25 minutes.
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
GLP-2 receptor Hs Agonist Agonist 10.6 pEC50 - 3
pEC50 10.6 (EC50 2.8x10-11 M) [3]
Description: Determined in a reporter assay using HEK293 cells stably overexpressing a cAMP response element (CRE) driven luciferase reporter and human GLP-2R.